Kamada Ltd.
corporate_fare Company Profile
Kamada Ltd. (NASDAQ:KMDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for KMDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-06, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for KMDA spans 6-K, 4, 20-F.
Recent high-impact activity:
- Kamada Doubles Israeli Biosimilar Portfolio, Sets $20M-$25M Revenue Target by 2030
- Kamada Launches Two New Biosimilars in Israel, Targets $25M Annual Revenue by 2030
- Director David Tsur Sells $1.46M of Kamada Shares
- Kamada CFO Chaime Orlev to Depart After 9 Years; Q2 Revenue Rises 23%
- Kamada Q2 Revenue Beats by 8%, Reaffirms 2026 Outlook
Financial Snapshot
Short Interest & Short Volume
2.47 days to coverFINRA reported short interest of 197,486 shares in KMDA as of the October 15, 2026 settlement, a 5.7% decrease from the prior period — about 2.5 days to cover at its recent average daily volume. On November 2, 2026, 45.8% of KMDA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for KMDA, detected from its recent SEC filings.
New $50M Shelf Registration Filed · No Immediate Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
KMDA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.